Knocking out the GHRH gene in mice increased both pain sensitivity and inflammatory responses, revealing a previously underappreciated protective role for this peptide hormone beyond growth hormone regulation.
Increased pain and inflammation across all modelsGHRH knockout mice showed heightened responses in every pain and inflammation test — hot plate, formalin, DSS colitis, and LPS stimulation — suggesting GHRH has a consistent protective role against both nociception and inflammatory pathways.
What the researchers found
Mice lacking the growth hormone-releasing hormone (GHRH) gene showed increased sensitivity to both pain and inflammation compared to normal mice. GHRH knockout mice had decreased response latency on the hot plate test (faster pain response), increased licking/biting during the formalin test (especially in the inflammatory phase), and significantly greater colonic inflammation after DSS treatment. Inflammatory markers — PGE2, 8-iso-PGF2α, COX-2, and TNF-α — were all elevated more dramatically in knockout mice, both in vivo and ex vivo.
Why it matters
GHRH is primarily known for stimulating growth hormone release, but this study reveals it also plays a protective role against pain and inflammation. This finding has implications for understanding why people with growth hormone deficiency often experience increased pain sensitivity and inflammatory conditions, and it opens potential new therapeutic avenues where GHRH or its analogs could be used for anti-inflammatory or analgesic purposes beyond their traditional endocrine applications.
How the study worked
GHRH knockout (-/-) mice were compared to wild-type (+/+) controls across multiple pain and inflammation models: hot plate test for acute nociception, formalin test for acute and persistent inflammatory pain, and dextran sodium sulfate (DSS)-induced colitis for chronic intestinal inflammation. Ex vivo colon segments were incubated with LPS to assess inflammatory response. Outcome measures included behavioral responses, macroscopic and histological examination, PGE2 and 8-iso-PGF2α levels, and COX-2 and TNF-α gene expression.
Who was studied
Male GHRH knockout mice and wild-type controls
What this study cannot tell us
This is a preclinical mouse study using constitutive gene knockout, meaning GHRH was absent throughout development — not just acutely suppressed. Developmental effects may confound the interpretation. Results were obtained only in male mice, limiting generalizability. The study demonstrates correlation between GHRH absence and increased pain/inflammation but cannot distinguish direct GHRH effects from secondary consequences of growth hormone deficiency. Specific numerical data (effect sizes, p-values) for behavioral tests are not detailed in the abstract.
How to read the evidence
This is a preclinical study using genetically modified mice with multiple validated pain and inflammation models. The consistency across different experimental paradigms strengthens the findings, but the constitutive knockout design and male-only study are limitations. No human data is available.
When this study was published
Published in 2019, this study contributes to the growing body of evidence that hypothalamic peptide hormones have significant non-endocrine functions. Research into GHRH's anti-inflammatory properties is still in early stages.
The bigger picture
GHRH analogs like tesamorelin are already used clinically for growth hormone-related conditions. This study suggests these peptides may have untapped anti-inflammatory and analgesic properties. Understanding the non-endocrine roles of hypothalamic peptides like GHRH could lead to repurposing existing peptide drugs for pain and inflammatory conditions — a growing area of interest as researchers discover that many hormone peptides have broader physiological roles than originally thought.
Questions still open
- Would administration of exogenous GHRH or GHRH analogs reduce pain sensitivity and inflammation in normal or GH-deficient animals?
- Is the increased pain and inflammation directly due to GHRH absence, or is it a downstream effect of chronic growth hormone deficiency?
- Do human patients with GHRH or GH deficiency show increased pain sensitivity and inflammatory disease prevalence?
Common questions
What is GHRH and what does it normally do?
Could GHRH-based drugs be used to treat pain or inflammation?
Read the original research
Increased pain and inflammatory sensitivity in growth hormone-releasing hormone (GHRH) knockout mice.
Prostaglandins & other lipid mediators, 144, 106362
Citation
Leone, Sheila; Chiavaroli, Annalisa; Recinella, Lucia; Orlando, Giustino; Ferrante, Claudio; Marconi, Guya Diletta; Gasparo, Irene; Bitto, Alessandra; Salvatori, Roberto; Brunetti, Luigi. (2019). Increased pain and inflammatory sensitivity in growth hormone-releasing hormone (GHRH) knockout mice.. Prostaglandins & other lipid mediators, 144, 106362. https://doi.org/10.1016/j.prostaglandins.2019.106362